Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRD5529
- Development stage
- Preclinical
- Lead developer
- Broad Institute
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
BRD5529 is a small-molecule inhibitor of the caspase recruitment domain-containing protein 9 (CARD9) pathway. Developed by the Broad Institute, BRD5529 acts as a protein-protein interaction (PPI) inhibitor that disrupts the binding of CARD9 to the E3 ubiquitin ligase TRIM62 (tripartite motif-containing protein 62). By preventing TRIM62-mediated ubiquitination of CARD9, BRD5529 blocks downstream NF-κB activation and the subsequent release of proinflammatory cytokines. It has been investigated preclinically for the treatment of inflammatory bowel disease (IBD), axial spondyloarthritis (axSpA), and Pneumocystis pneumonia (PCP)-related lung injury.
02
Targets
CARD9 (Caspase recruitment domain-containing protein 9)
Beyond the preview
Go deeper on BRD5529.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRD5529.